Template:Published case reports of cyproterone acetate-associated prolactinoma

From Wikipedia, the free encyclopedia
Published case reports of cyproterone acetate-associated prolactinoma
# Age Sex Medications Treatment duration Ref Link
1 26 years MtF CPA 100 mg/day, EE 100 μg/day, EU 100 mg/2x week ~10 months Gooren et al. (1988) [1]
2 32 years MtF CPA 150 mg/day, EE 1.5 mg/day 4 years Serri et al. (1996) [2]
3 52 years MtF CPA 100 mg/day, EE 100 μg/day 15 years Bunck et al. (2009) [3]
4 33 years MtF CPA 200 mg/day, CEEs 2.5 mg/day 6 months García-Malpartida et al. (2010) [4]
5 41 years MtF CPA 2 mg/day, EE 35 μg/day, E2-EN 10 mg/2 weeks i.m. 18 years Cunha et al. (2015) [5]
6 32 years MtF CPA 100 mg/day, E2 injections 100 mg/2 weeks i.m. 53 months Nota et al. (2018) [6]
7 39 years MtF CPA 100 mg/day, CEEs 2.5 mg/day 172 months Nota et al. (2018) [6]
8 27 years MtF CPA, E2 injections i.m. (no dosage information) 156 months Nota et al. (2018) [6]
9 46 years MtF CPA 100 mg/day, EE 100 μg/day 66 months Nota et al. (2018) [6]
10 24 years MtF CPA 100 mg/day (no estrogen mentioned) 9 months Nota et al. (2018) [6]
11 47 years MtF CPA 100 mg/day, EE 100 μg/day 91 months Nota et al. (2018) [6]
12 28 years MtF CPA 50 mg/day, EV 2 mg/day oral 134 months Nota et al. (2018) [6]
13a 34 years MtF CPA 50 mg/day, EV 1 mg/day oral 35 months Nota et al. (2018) [6]
Abbreviations: CPA = Cyproterone acetate. E2 = Estradiol. EV = Estradiol valerate. E2-EN = Estradiol enanthate. EU = Estradiol undecylate. CEEs = Conjugated estrogens. EE = Ethinylestradiol. MtF = Male-to-female (transgender woman). i.m. = Intramuscular injection. Footnotes: a = Non-secretive pituitary adenoma. Notes: Asscheman et al. (1988) also described 5 MtF cases of pituitary enlargement and possible prolactinoma.[7] van Kesteren et al. (1997) described possible MtF cases of pituitary enlargement as well.[8] Five estrogen-only MtF cases (without CPA) have also been reported.[9][3][5][6] Futterweit (1998) described an MtF case without information about medications.[10] Sources: [11]